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Brazilian 2011GDP per capita), VO was the only cost-effective option compared to 
AB, additionally presenting lower mortality and less hospitalization days while 
allowing early de-hospitalization at private health care services.  
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OBJECTIVES: Influenza results in excess morbidity and mortality and therefore 
causes significant burden in a society. Outcomes of the influenza vaccination 
program are influenced by patient acceptance to receive the vaccine. The cost-
effectiveness of influenza vaccine at preventing hospitalization for lower 
respiratory infections in Hong Kong was examined at different levels of 
vaccination coverage. METHODS: A decision model was designed to simulate the 
outcomes of influenza vaccination programs at four different levels of 
vaccination coverage in a hypothetical cohort of elderly aged 65-year-old or 
above who have with no contraindications for influenza vaccine: 1) 16% (current 
vaccination coverage rate in Hong Kong); 2) 35% (vaccination coverage rate in 
some Asian countries; 3) 65%; and 4) 100%. The time horizon was one year. 
Model inputs were derived from literature, and outcome measures were direct 
medical cost (including vaccination) from the health care provider’s perspective, 
influenza-associated mortality rate, and quality-adjusted life-year (QALY) 
gained. Robustness of model results was examined by sensitivity analysis. 
RESULTS: In the base-case scenario, 100% vaccination coverage was associated 
with the lowest cost (USD6.92), the lowest influenza-associated mortality rate 
(0.30 deaths per 10,000 persons) and the highest QALYs gained (0.8358), followed 
by 65% coverage rate (USD8.08; 0.35 deaths per 10,000 persons; 0.8351 QALYs), 
35% coverage rate (USD9.07; 0.39 deaths per 10,000 persons; 0.8345 QALYs) and 
16% rate (USD9.70; 0.42 deaths per 10,000 persons; 0.8342 QALYs). The results 
were robust to variation of all model inputs in sensitivity analysis. 
CONCLUSIONS: In the present model, high coverage rate of influenza 
vaccination seems to be associated with lower direct medical cost, lower 
influenza-associated deaths and higher QALYs.  
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OBJECTIVES: HEPLISAV is an investigational hepatitis B virus (HBV) vaccine with 
an adjuvant that specifically targets toll-like receptor 9 and in clinical studies 
provided more rapid and higher rates of seroprotection with fewer doses 
compared with currently available vaccines. We modeled the cost-effectiveness 
of vaccination with HEPLISAV compared with Engerix-B in the prevention of HBV 
infection in select adult populations. METHODS: A Markov model was developed 
for each population of interest: diabetics, patients with chronic or end stage 
kidney disease, health care workers and international travelers to countries with 
high HBV infection prevalence. Disease progression was modeled using 11 health 
states: seroprotected, susceptible, acute infection, chronic infection, fulminant 
hepatic failure, compensated cirrhosis, decompensated cirrhosis, hepatocellular 
carcinoma, liver transplant, post-transplant care, and death. Seroprotection rates 
were based on results from two phase 3 clinical trials comparing HEPLISAV with 
Engerix-B and ranged across the various populations from 89-96% for HEPLISAV 
and 62-81% for Engerix-B. Higher vaccination completion rates were assumed for 
HEPLISAV compared with Engerix-B given that fewer doses of HEPLISAV are 
required in a shorter period of time to achieve seroprotection for the evaluated 
populations. Each cycle length represented a 1-year time frame. All future costs 
and benefits were discounted at 3%. A lifetime analysis and a U.S. payer 
perspective were used in this study. RESULTS: HEPLISAV has a favorable cost-
effectiveness profile with incremental cost-effectiveness ratios <$20,000 across 
all populations studied. In the patients with chronic or end stage kidney disease, 
HEPLISAV was the dominant option and was cost-saving compared with Engerix-
B. The cost of vaccine, regimen completion rates, and seroprotection rates were 
the sensitive variables in the models. CONCLUSIONS: HEPLISAV may be a cost-
effective option for HBV vaccination to provide high rates of seroprotection and 
early seroprotection across a range of populations from health care workers to 
patients with chronic or end stage kidney disease.  
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BACKGROUND: For first-line HIV treatment, US treatment guidelines state that 
efavirenz (EFV) is the only preferred non-nucleoside reverse transcriptase 
inhibitor (NNRTI) while nevirapine (NVP) is listed as an acceptable NNRTI. 
Generic versions of NVP were first approved in the US in May 2012. OBJECTIVES: 
To assess the cost-effectiveness of EFV compared with generic NVP in first-line 
HIV treatment in the US. METHODS: A micro-simulation state transition model 
was constructed to estimate the costs (2012 US$) and clinical outcomes for 
antiretroviral naïve HIV patients initiating EFV or NVP. Efficacy and safety data 
was based on the HIV Causal Collaboration Study and a Cochrane Review. 
Published sources were used to identify other inputs. Costs included 
antiretroviral drug acquisition, disease management (based on CD4 counts) and 
adverse events. Health utility was based on CD4 counts and adverse events. A 3% 
discount rate was used for costs and quality-adjusted life years (QALYs). Results 
are based on 100,000 micro-simulation trials with a ten year time horizon. 
RESULTS: Over a 10-year period, EFV was dominant over NVP in the base case 
with lower total costs ($346,932 vs. $364,475), modestly higher QALYs (6.795 vs. 
6.782), and similar life expectancy (9.346 vs. 9.342 years). Keeping all other inputs 
constant, EFV was dominant over generic NVP until the price of NVP was 
reduced to 50% of its base case value. Giving EFV and NVP equal probability of 
treatment success but maintaining basecase adverse event rates and costs 
resulted in an incremental cost effectiveness ratio of $4,438 for EFV compared to 
NVP. CONCLUSIONS: Over a 10-year time horizon, EFV was predicted to be cost-
saving compared to generic NVP with modestly higher QALYs and similar life 
expectancy in HIV patients initiating first-line treatment in the US. Sensitivity 
analysis indicated results were not sensitive to NVP price changes.  
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OBJECTIVES: Skin and soft tissue infections caused by Staphylococcus aureus and 
Streptococcus pyogenes are a growing concern in Latin America due to the 
development of more complex resistance profiles to standard antibiotics. The 
aim of this analysis is to estimate the cost-effectiveness of Linezolid in the 
treatment of complicated skin and soft tissue infections (cSSTI) in Colombia. 
METHODS: A decision tree was built to estimate the incremental cost-
effectiveness ratio of the Linezolid (600 IV/twice day) switch (600 orally/twice 
day) compared to Vancomycin (1 g IV/twice day), Daptomycin (4 mg IV/kg/day) 
and Tigecycline (100 mg IV followed by 50 mg twice day). The perspective was 
third payer including direct medical costs only. Effectiveness, safety and utility 
data were extracted from published literature. Unit costs were taken from health 
care institutions. Resource use and costs (drug acquisition, inpatient stay, health 
care professional visits, and lab tests) were considered for the model and 
expressed in 2012 US$. Time horizon was 28 days and effectiveness measures 
were quality-adjusted life-year (QALY’s) and percentage of patients cured. 
RESULTS: Total expected costs for each alternative were: Linezolid US$8,221.7, 
Vancomycin US$10,236.96; Daptomycin US$11,359.69 and Tigecycline 
US$11,255.92. Patients treated with Linezolid were associated with a shorter 
length of stay in the intensive care unit (7 days on average) which reduces 
overall treatment costs due it allows cSSTI patients switching from intravenous 
to oral administration (5 days reduction on average). Results for each alternative 
in terms of QALYs were: Linezolid 0.063, Vancomycin 0.060, Daptomycin 0.061 
and Tigecycline 0.059. Results for each alternative in terms of percentage of 
patients cured were: Linezolid 84.4%; Vancomycin 74.7%; Daptomycin 78.1% and 
Tigecycline 70.4%. The model results indicate that Linezolid would be a 
dominant treatment compared to Vancomycin, Daptomycin and Tigecycline. 
CONCLUSIONS: Linezolid seems to be a cost-saving option for the treatment of 
cSSTI in Colombia.  
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OBJECTIVES: For first-line treatment of HIV, US treatment guidelines 
recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir 
(EFV/FTC/TDF) as a preferred regimen and the once-daily tablet of 
elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/cobi/FTC/TDF) as an 
alternative regimen. This study assessed the clinical and economic trade-offs 
involved in using EVG/cobi/FTC/TDF compared with EFV/FTC/TDF in first-line 
HIV antiretroviral therapy (ART) in US adults. METHODS: A Markov cohort model 
was developed to project lifetime health-related outcomes, costs, quality-
adjusted life years (QALYs), and cost-effectiveness of EVG/cobi/FTC/TDF 
compared with EFV/FTC/TDF as first-line ART in the US. HIV patients progressed 
in 12-week cycles through second-line, third-line, and non-suppressive 
therapies, AIDS, and death. Baseline characteristics and first-line virologic 
suppression, change in CD4 count, and adverse effects (lipid, central nervous 
system, rash, and/or renal) were based on 48-week clinical trial results. These 
results demonstrated equivalent virologic suppression between the two 
regimens. Point estimates for virologic suppression (favoring EVG/cobi/FTC/TDF) 
were used in the base case, and equivalency in scenario analysis. Published 
sources and expert opinion were used to estimate costs, utilities, AIDS risk, 
mortality, and subsequent-line CD4 count, efficacy and adverse events. Costs 
were reported in 2012 US dollars. Sensitivity analyses were conducted to assess 
robustness of results. RESULTS: Compared with patients initiating EFV/FTC/TDF, 
patients initiating EVG/cobi/FTC/TDF were estimated to have higher lifetime 
costs. EVG/cobi/FTC/TDF added 0.087 QALYs over a lifetime at a cost of $10,843, 
producing an incremental cost-effectiveness ratio of $124,101/QALY gained. 
Results were most sensitive to first-line response, product costs, and likelihood 
of renal adverse events. When equivalent efficacy was assumed, EFV/FTC/TDF 
dominated EVG/cobi/FTC/TDF with lower costs (-$12,305) and greater QALYs 
(0.047). CONCLUSIONS: At a societal willingness to pay of $100,000/QALY, 
EVG/cobi/FTC/TDF was not cost effective in the base case compared with 
